- Home
- CANF vs NERV Comparison
CANF vs NERV Comparison
Compare CANF & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- NERV
- Stock Information
- Founded
- CANF 1994
- NERV 2007
- Country
- CANF Israel
- NERV United States
- Employees
- CANF N/A
- NERV N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- NERV Health Care
- Exchange
- CANF Nasdaq
- NERV Nasdaq
- Market Cap
- CANF 13.5M
- NERV 12.0M
- IPO Year
- CANF N/A
- NERV 2014
- Fundamental
- Price
- CANF $0.66
- NERV $1.91
- Analyst Decision
- CANF Strong Buy
- NERV Hold
- Analyst Count
- CANF 2
- NERV 1
- Target Price
- CANF $14.00
- NERV $5.00
- AVG Volume (30 Days)
- CANF 314.0K
- NERV 20.9K
- Earning Date
- CANF 08-29-2025
- NERV 08-12-2025
- Dividend Yield
- CANF N/A
- NERV N/A
- EPS Growth
- CANF N/A
- NERV N/A
- EPS
- CANF N/A
- NERV 0.83
- Revenue
- CANF $674,000.00
- NERV N/A
- Revenue This Year
- CANF $461.72
- NERV N/A
- Revenue Next Year
- CANF N/A
- NERV N/A
- P/E Ratio
- CANF N/A
- NERV $2.32
- Revenue Growth
- CANF N/A
- NERV N/A
- 52 Week Low
- CANF $0.63
- NERV $1.15
- 52 Week High
- CANF $3.24
- NERV $3.00
- Technical
- Relative Strength Index (RSI)
- CANF 12.02
- NERV 51.54
- Support Level
- CANF $1.00
- NERV $1.87
- Resistance Level
- CANF $1.05
- NERV $2.32
- Average True Range (ATR)
- CANF 0.05
- NERV 0.15
- MACD
- CANF -0.04
- NERV -0.01
- Stochastic Oscillator
- CANF 5.86
- NERV 28.76
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.